The effectiveness of low laser therapy in subacromial impingement syndrome: a randomized placebo controlled double-blind prospective study
Citation
Dogan, S. K., Ay, S., & Evcik, D. (2010). The effectiveness of low laser therapy in subacromial impingement syndrome: a randomized placebo controlled double-blind prospective study. Clinics, 65(10), 1019–1022. https://doi.org/10.1590/s1807-59322010001000016Abstract
OBJECTIVES: Conflicting results were reported about the effectiveness of Low level laser therapy on musculoskeletal
disorders. The aim of this study was to investigate the effectiveness of 850-nm gallium arsenide aluminum (Ga-As-Al)
laser therapy on pain, range of motion and disability in subacromial impingement syndrome.
METHODS: A total of 52 patients (33 females and 19 males with a mean age of 53.59¡11.34 years) with subacromial
impingement syndrome were included. The patients were randomly assigned into two groups. Group I (n = 30, laser
group) received laser therapy (5 joule/cm2 at each point over maximum 5-6 painful points for 1 minute). Group II
(n = 22, placebo laser group) received placebo laser therapy. Initially cold pack (10 minutes) was applied to all of the
patients. Also patients were given an exercise program including range of motion, stretching and progressive
resistive exercises. The therapy program was applied 5 times a week for 14 sessions. Pain severity was assessed by
using visual analogue scale. Range of motion was measured by goniometer. Disability was evaluated by using
Shoulder Pain and Disability Index.
RESULTS: In group I, statistically significant improvements in pain severity, range of motion except internal and
external rotation and SPADI scores were observed compared to baseline scores after the therapy (p,0.05). In Group
II, all parameters except range of motion of external rotation were improved (p,0.05). However, no significant
differences were recorded between the groups (p.0.05).
CONCLUSIONS: The Low level laser therapy seems to have no superiority over placebo laser therapy in reducing pain
severity, range of motion and functional disability.